XML 75 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Segments (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Expenses by Segment

In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories (in thousands):

Research and Development

 

Year Ended December 31,

 

 

2024

 

 

2023

 

 

(in thousands)

 

Clinical trial-related activities

 

$

36,632

 

 

$

32,449

 

Personnel

 

 

19,701

 

 

 

17,276

 

Chemistry, manufacturing and control

 

 

11,350

 

 

 

14,865

 

Preclinical studies and activities

 

 

1,629

 

 

 

1,267

 

Consultants and other costs

 

 

2,172

 

 

 

1,972

 

Total research and development expenses

 

$

71,484

 

 

$

67,829

 

General and Administrative

 

Year Ended December 31,

 

 

2024

 

 

2023

 

 

(in thousands)

 

Personnel

 

$

11,367

 

 

$

10,294

 

Professional services

 

 

4,847

 

 

 

4,469

 

Consultants and other costs

 

 

7,479

 

 

 

8,851

 

Total general and administrative expenses

 

$

23,693

 

 

$

23,614